2026 Interim report
Filed with HKEX · Stock code 9860 · · 61 pages · English
Summary by 6ix AI
The report highlights a slight increase in revenue compared to the same period last year, alongside improvements in gross profit and net profit margins. The CEO's statement emphasizes the company's strategic focus on organic and inorganic growth, particularly in the context of the evolving healthcare landscape in China. The management discussion outlines significant progress in various business segments, including co-construction and CRO services, which have shown notable revenue growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ADICON Holdings Limited on 6ix
Earlier from ADICON
Later from ADICON
- Major acquisition in relation to acquisition of 100% of the issued shares of the target company - extension of outside date
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Major acquisition in relation to acquisition of 100% of the issued shares of the target company - termination of the share purchase agreement
Follow ADICON into a list and get an email when it puts out news.
Follow ADICON